Abstract
Cancer research is occasionally described as being in a reproducibility crisis. The cancer literature has ample papers retracted due to misconduct, including the use of paper mills, invalid authorship, or fake data. The objective of this paper was to gain an appreciation of the balance of retractions and associated retraction notices of 23 retracted Cancer Biotherapy and Radiopharmaceuticals papers associated with paper mills. By 23 March 2023, these retracted papers had already accumulated 287 citations according to Web of Science Core Collection, 253 according to Scopus, and 365 according to Google Scholar, i.e., metrically speaking, they were highly rewarded. All authors had an affiliation (71% being a hospital) in China. Most (12/21; 57%) of corresponding authors had emails with a @163.com suffix. Four of the retraction notices (i.e., 17%) explicitly indicated paper mills as a reason for retraction although, in general, the retraction notices lacked details and background that could assist readers’ understanding of the retractions.